Teva's Exclusivity For Cozaar And Hyzaar Generics Imperiled Once Again
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA tells court it is considering whether the fact that the patent has expired because Merck did not pay maintenance fees means that Teva could lose its 180-day prize.
You may also be interested in...
FDA Reluctantly Grants Teva Exclusivity For Cozaar And Hyzaar Generics
The agency says it has no choice but to award Teva exclusivity given an appeals court decision limiting forfeiture; Apotex has not decided whether it will challenge the court's ruling.
FDA Reluctantly Grants Teva Exclusivity For Cozaar And Hyzaar Generics
The agency says it has no choice but to award Teva exclusivity given an appeals court decision limiting forfeiture; Apotex has not decided whether it will challenge the court's ruling.
FDA's Generic Drugs Office Faces Transition As Director Buehler Departs
FDA's Office of Generic Drugs is poised to enter a new era with new leadership, even as the agency is saying it will draw on the expertise of veteran officials for key initiatives